Exhibit 10.21
PATENT PURCHASE
AGREEMENT
This PATENT PURCHASE AGREEMENT
(“Agreement”) is entered into on April 6, 2005 (“
Effective Date ”) by and between Faust
Communications, LLC, with an office at [***] (“
Purchaser ”), and NeoMagic Corporation with an
office at 3250 Jay Street, Santa Clara, CA 95054 (“
Seller ”). The parties hereby agree as
follows.
1. B ACKGROUND
1.1 Seller owns certain United States Letters
Patents and/or applications for United States Letters Patents
and/or related foreign patents and applications.
1.2 Seller wishes to sell its right, title and
interest in such patents and applications to Purchaser.
1.3 Purchaser wishes to purchase such patents
and applications.
2. D EFINITIONS
2.1 “ Assignment Agreements
” means the agreements assigning ownership of the Patents
from the inventors and/or prior owners to Seller.
2.2 “Closing Date”
means the date on which Purchaser has paid the Seller the total
Purchase Price.
2.3 “ List of Prosecution
Counsel ” means the names and addresses of
prosecution counsel who prosecuted the Patents and who are
currently handling the Patents.
2.4 “ Patents ” means
those patents and applications listed in Exhibit A
hereto, and all reissues, reexaminations, extensions,
continuations, continuations in part, continuing prosecution
applications, and divisions of such patents and applications;
provisional patent applications that are or will be continuations
or continuations in part of such patents and applications; and
foreign counterparts to any of the foregoing including without
limitation utility models.
2.5 “ Purchase Price ” means
Four Million Five Hundred and Fifty Thousand Dollars (USD
4,550,000).
3. D ELIVERY AND P AYMENT
3.1 Delivery . On the Effective Date,
Seller shall deliver an executed original of the Assignment of
Patent Rights in Exhibit B hereto to
Purchaser.
|
[***]
|
Confidential
treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the
Commission.
|
3.2 Payment . On the Effective Date,
Purchaser shall pay to Seller the Purchase Price.
4. T RANSFER OF P ATENTS
4.1 Patent Assignment . Effective on the
Closing Date, Seller hereby sells, assigns, transfers and conveys
to Purchaser all right, title and interest it has in and to the
Patents and all inventions and discoveries described therein,
including without limitation, all rights of Seller under the
Assignment Agreements, and all rights of Seller to collect
royalties under such Patents.
4.2 Assignment of Causes of Action .
Effective on the Closing Date, Seller hereby sells, assigns,
transfers and conveys to Purchaser all right, title and interest it
has in and to all causes of action and enforcement rights, whether
currently pending, filed, or otherwise, for the Patents and all
inventions and discoveries described therein, including without
limitation all rights to pursue damages, injunctive relief and
other remedies for past, current and future infringement of the
Patents.
4.3 Grant Under Patent Rights . Effective
on the Closing Date, Purchaser hereby grants to Seller, under the
Patent Rights (as defined in Exhibit B hereto), and for the lives
thereof, a royalty-free, irrevocable, non-exclusive,
non-transferable (except as permitted under Section 4.3 below),
worldwide right and license (the “ Seller
License ”) to practice the methods and to make, have
made, use, distribute, lease, sell, offer for sale, import, export,
develop and otherwise dispose of and exploit any products,
processes or services covered by the Patent Rights (“
Covered Products ”). This Seller License shall
also apply to the reproduction and subsequent distribution of
Covered Products, in substantially identical form as they are
distributed by the Seller, by authorized agents of the Seller such
as a distributor, replicator, VAR or OEM.
4.4 Limitation on Transferability. The
Seller License in Section 4.3 above may be transferred one time to
a purchaser of all, or substantially all, of Seller’s
operating assets (other than cash) which are covered by the Seller
License, or to a party that by merger or otherwise, acquires all,
or substantially all, of Seller’s outstanding capital stock
(any such transaction referred to as the “ Acquisition
” and any such purchaser or acquiring party referred to as
the “ Assignee ”). In the event of such
Acquisition, the Seller License shall automatically become limited
to the Covered Products of (1) Seller that are either under
development or that are commercially released on the effective date
of such Acquisition and (2) Assignee that are commercially released
as of the effective date of the Acquisition and, for each of (1)
and (2) any new versions that have merely incremental differences
from Seller’s and Assignee’s Covered Products covered
by the Seller License on the effective date of the Acquisition (all
such products, processes and services referred to collectively as
the “ Covered Items ”). In no event, however,
shall the Seller License be construed or interpreted to include any
other products, processes or services of the Seller, Assignee or
any other third party. The Seller License with respect to the
Covered Items shall automatically terminate upon any subsequent
Acquisition by any third party (“ Subsequent
Acquisition ”), provided that the Seller License shall
continue in full force and effect with respect to any
commercially
|
[***]
|
Confidential
treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the
Commission.
|
- 2 -
released Covered Items of Seller or Assignee
that are in inventory or are in production on the effective date of
any Subsequent Acquisition. Seller or Assignee shall provide
Purchaser written notice within one hundred and twenty (120) days
of the Seller License being transferred under this Section 4.4 and
specifically detail the Covered Items as of the effective date of
the Acquisition. If Purchaser is not so notified of such transfer
of the Seller License within one hundred and twenty (120) days of
the effective date of Acquisition, the Seller License under Section
4.3 shall automatically terminate.
5. A DDITIONAL O BLIGATIONS
5.1 Further Assurances . At the
reasonable request of Purchaser and without demanding further
consideration from Purchaser, Seller agrees to execute and deliver
such other instruments and do and perform such other acts and
things as may be reasonably necessary for effecting completely the
consummation of the transfer of ownership in and to the Patents as
contemplated hereby, including without limitation execution,
acknowledgment and recordation of other such papers, and using all
reasonable best efforts to obtain the same from the respective
inventors, as necessary or desirable for fully perfecting and
conveying unto Purchaser the benefit of the transfer of ownership
in and to the Patents as contemplated hereby.
5.2 Further Assistance . Subject to the
terms and conditions hereof, Seller agrees, upon the reasonable
request of Purchaser, to do all things necessary, proper, or
advisable, including without limitation the execution,
acknowledgment and recordation of specific assignments, oaths,
declarations and other documents on a country-by-country basis, to
assist Purchaser in obtaining, perfecting, sustaining, and/or
enforcing the Patent Rights. Such assistance may also include
providing, and obtaining from the respective inventors, prompt
production of pertinent facts and documents, giving of testimony,
execution of petitions, oaths, powers of attorney, specifications,
declarations or other papers and other assistance reasonably
necessary for filing patent applications, complying with any duty
of disclosure, and conducting prosecution, reexamination, reissue,
interference or other priority proceedings, opposition proceedings,
cancellation proceedings, public use proceedings, infringement or
other court actions and the like with respect to the Patent Rights.
Seller’s agreement to render any of the foregoing assistance
is subject to Purchaser’s payment of all reasonable expenses
of Seller incurred in connection therewith and the availability of
Seller’s personnel.
5.3 Payment of Fees . Seller shall pay
any maintenance fees, annuities, and the like due on the Patents
for a period of thirty (30) calendar days following the Effective
Date.
|
[***]
|
Confidential
treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the
Commission.
|
- 3 -
6. R EPRESENTATIONS AND W ARRANTIES
Seller hereby warrants to Purchaser
as follows:
6.1 Authority . Seller has the right and
authority to enter into this Agreement and to carry out its
obligations hereunder.
6.2 Title and Contest . Seller has good
and marketable title to the Patents, including without limitation
all rights, title, and interest in the Patents to sue for
infringement thereof. The Patents are free and clear of all liens,
mortgages, security interests or other encumbrances, and
restrictions on transfer. There are no actions, suits, claims or
proceedings threatened, pending or in progress on the part of any
named inventor of the Patents relating in any way to the Patents
and Seller has not received notice of (and Seller is not aware of
any facts or circumstances which could reasonably be expected to
give rise to) any other actions, suits, investigations, claims or
proceedings threatened, pending or in progress relating in any way
to the Patents. There are no existing contracts, agreements,
options, commitments, proposals, bids, offers, or rights with, to,
or in any person to acquire any of the Patents.
6.3 Existing Licenses . No rights or
licenses have been granted under the Patents.
6.4 Restrictions on Rights . Purchaser
will not be subject to any covenant not to sue or similar
restrictions on its enforcement or enjoyment of the Patents as a
result of the transaction contemplated in this Agreement, or any
prior transaction related to the Patents.
6.5 Conduct . To Seller’s
knowledge, none of Seller or its representatives has engaged in any
conduct, or omitted to perform any necessary act, the result of
which would invalidate any of the Patents or hinder their
enforcement, including but not limited to misrepresenting
Seller’s patent rights to a standard-setting
organization.
6.6 Enforcement . Seller has not put a
third party on notice of actual or potential infringement of any of
the Patents or considered enforcement action(s) with respect to any
of the Patents.
6.7 Patent Office Proceedings . None of
the Patents have been or are currently involved in any
reexamination, reissue, interference proceeding, or any similar
proceeding and that no such proceedings are pending or
threatened.
6.8 Related Assets. There are no other
patents issued and/or applications pending for or on behalf of
Seller which are subject to a Terminal Disclaimer under 37 C.F.R.
§1.321 that require any of such patents issued and/or
applications and any of the Patents conveyed in this Agreement to
remain under common ownership.
|
6.9
|
Fees .
All maintenance fees, annuities, and the like due on the Patents
have been timely paid through the Effective Date.
|
|
[***]
|
Confidential
treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the
Commission.
|
- 4 -
6.10 Validity and Enforceability . To
Seller’s knowledge, the Patents have never been found invalid
or unenforceable for any reason in any administrative, arbitration,
judicial or other proceeding, and Seller has not received any
notice or information of any kind from any source suggesting that
the Patents may be invalid or unenforceable.
7. M ISCELLANEOUS
7.1 No Representation or Warranty .
SELLER MAKES NO REPRESENTATIONS OR WARRANTIES WHATSOEVER THAT ANY
OF THE PATENTS COVERED BY THIS AGREEMENT ARE EITHER VALID OR ARE
INFRINGED BY ANY OTHER PARTIES.
7.2 Limitation on Consequential Damages. EXCEPT
IN THE CASE OF FRAUD BY SELLER, NEITHER PARTY SHALL BE LIABLE TO
THE OTHER FOR LOSS OF PROFITS, OR ANY OTHER INDIRECT OR SPECIAL,
CONSEQUENTIAL, PUNITIVE OR INCIDENTAL DAMAGES, HOWEVER CAUSED, EVEN
IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. THE PARTIES
ACKNOWLEDGE THAT THESE LIMITATIONS ON POTENTIAL LIABILITIES WERE AN
ESSENTIAL ELEMENT IN SETTING CONSIDERATION UNDER THIS
AGREEMENT
7.3 Limitation of Liability . EXCEPT IN
THE CASE OF FRAUD BY SELLER, IN NO EVENT SHALL EITHER PARTY’S
TOTAL LIABILITY UNDER THIS AGREEMENT EXCEED THE PURCHASE PRICE. THE
PARTIES ACKNOWLEDGE THAT THESE LIMITATIONS ON POTENTIAL LIABILITIES
WERE AN ESSENTIAL ELEMENT IN SETTING CONSIDERATION UNDER THIS
AGREEMENT.
7.4 Compliance with Laws .
Notwithstanding anything contained in this Agreement to the
contrary, the obligations of the parties shall be subject to all
laws, present and future, of any government having jurisdiction
over the parties and this transaction, and to orders, regulations,
directions or requests of any such government.
7.5 Confidentiality of Terms . The
parties hereto shall keep the terms and existence of this Agreement
and the identities of the parties hereto confidential and shall not
now or hereafter divulge any of this information to any third party
except: (a) with the prior written consent of the other party, such
consent shall not be unreasonably withheld; (b) as otherwise may be
required by law or legal process, including in confidence to
financial advisors in their capacity of advising a party in such
matters; (c) during the course of litigation, so long as the
disclosure of such terms and conditions are restricted in the same
manner as is the confidential information of other litigating
parties; or (d) in confidence to its legal counsel, accountants,
banks and financing sources and their advisors solely in connection
with complying with financial transactions; provided that, in (b)
through (d) above, (i) the disclosing party shall use all
legitimate and legal means available to minimize the disclosure to
third parties, including without limitation seeking a confidential
treatment request or protective order whenever appropriate or
available; and (ii), other than disclosures
|
[***]
|
Confidential
treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the
Commission.
|
- 5 -
pursuant to subsection (d) above, the disclosing
party shall provide the other party with at least ten (10) days
prior written notice of such disclosure. The above notwithstanding,
Purchaser agrees that, on or after the Effective Date, Seller shall
be allowed to make one or more public announcements in order to
fulfill its requirements as a public company with respect to the
disclosure of this Agreement. Seller agrees that it will submit any
such announcements to Purchaser at least two (2) days prior to its
making those announcements for Purchaser’s approval, which
approval shall not be unreasonably withheld.
7.6 Governing Law . Any claim arising
under or relating to this Agreement shall be governed by the
internal substantive laws of the State of New York without regard
to principles of conflict of laws.
7.7 Jurisdiction . Each party hereby
agrees to jurisdiction and venue in the courts of the State of New
York or the Federal courts sitting therein for all disputes and
litigation arising under or relating to this Agreement.
7.8 Entire Agreement . The terms and
conditions of this Agreement, including its exhibits, constitutes
the entire agreement between the parties with respect to the
subject matter hereof, and merges and supersedes all prior and
contemporaneous agreements, understandings, negotiations and
discussions. Neither of the parties shall be bound by any
conditions, definitions, warranties, understandings, or
representations with respect to the subject matter hereof other
than as expressly provided herein. The section headings contained
in this Agreement are for reference purposes only and shall not
affect in any way the meaning or interpretation of this Agreement.
No oral explanation or oral information by either party hereto
shall alter the meaning or interpretation of this Agreement. No
amendments or modifications shall be effective unless in a writing
signed by authorized representatives of both parties. These terms
and conditions will prevail notwithstanding any different,
conflicting or additional terms and conditions which may appear on
any purchase order, acknowledgment or other writing not expressly
incorporated into this Agreement. This Agreement may be executed in
two (2) or more counterparts, all of which, taken together, shall
be regarded as one and the same instrument. The following exhibits
are attached hereto and incorporated herein: Exhibit
A (entitled “Patent Rights to be Assigned”) and
Exhibit B (entitled “Assignment of Patent
Rights”).
|
[***]
|
Confidential
treatment requested pursuant to a request for confidential
treatment filed with the Securities and Exchange Commission.
Omitted portions have been filed separately with the
Commission.
|
- 6 -
7.9 Notices: All no